18 to 70 years old at the time of signing the Informed Consent Form (ICF).
Diagnosed as Multiple sclerosis (MS)/Neuromyelitis Optica Spectrum Disorders (NMOSD)/Myasthenia Gravis (MG)/Systemic Lupus Erythematosus (SLE)/ Systemic Sclerosis (SSc)/ Immune-Mediated Necrotizing Myopathy (IMNM) according to recognized diagnostic criteria for at least 6 months.
Prior treatment failure with standard therapy.
Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function.
You may not be if
Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive, Epstein-Barr Virus (EBV) DNA positive.
Uncontrolled active infection.
Live vaccine injection within 4 weeks prior to signing the ICF.
Major organ transplantation history or bone marrow/hematopoietic stem cell transplantation history.
Severe cardiovascular diseases within the past 6 months prior to screening.
A history of ≥ Grade 2 bleeding within 4 weeks prior to screening, or requiring long-term anticoagulants treatment.
Inadequate washing time for previous treatment.
Previously treated with CAR-T cell products or genetically modified T cell therapies.
Pregnant or lactating women.
Severe central nervous system diseases or pathological changes.
Malignancy history within 5 years prior to signing the ICF.
Any contraindication to lumbar puncture for MS or NMOSD.
Clareo Health | A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
